Glenmark FY26: 27.5% Revenue Growth, but the Plot Thickens

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Glenmark’s FY26 told two stories with the same ending: a company escaping the gravity of its own balance sheet while pretending the innovation wager doesn’t exist yet.

Revenue hit ₹16,983 crore—a 27.5% surge over the prior year—but net profit crawled to ₹1,362 crore from ₹1,047 crore in FY25, a gain of only 30%. The gap between top-line velocity and bottom-line caution flags a business in transition: generics retreating, branded markets advancing, and a ₹700 crore upfront cheque from AbbVie sitting in deferred income, waiting for approvals that may never come in the form expected. Operating margins exploded to 27% in Q4 (a quarter so unusual it distorts the full-year read), but the annual operating profit of ₹4,085 crore masks a business where the core performed steadily while one-time licensing events made the numbers scream.

Gross debt vanished. Inventory spiked. Working capital returned to war footing. The company framed FY26 as “defining,” which is what most things become when you’ve bet the farm on biologics partnerships and need Wall Street to forget about the regulatory risks.

One question lurks: Does ₹1,200 crore of net cash bought with divestments actually resolve the ROCE equation, or is it just compressed air before the next capex wave?

2. Introduction

Glenmark Pharmaceuticals Limited arrived at FY26 as India’s 14th-largest pharma company, the 15th-largest generic filler in the United States by prescriptions, and the 5th-largest Indian exporter to Europe.

The company operates across 80+ countries, manufactures at 11 facilities globally (8 US FDA-approved), and manages a portfolio split between generics (about 40% of revenue), branded pharmaceuticals (especially strong in India and emerging markets), and a nascent specialty oncology franchise via its Ichnos subsidiary. Its therapeutic focuses—dermatology, respiratory, and oncology—map neatly onto profit pools that are growing faster than the company itself in many regions.

Between FY25 and FY26, the narrative inflected sharply. India’s generics market decelerated; US competitors commoditized; Europe demanded specialty differentiation. In response, management accelerated branded launches (RYALTRIS in allergic rhinitis, WINLEVI in acne/dermatology, oncology partnerships with AbbVie, Hengrui, and Hanso), restocked the US complex generics pipeline (respiratory, injectables), and extracted ₹700 crore from AbbVie for the lead oncology asset ISB 2001 in most territories outside the USA. The company also cut debt from ₹2,473 crore in FY25 to ₹594 crore by March 2026, partly through the ₹5,651 crore divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited.

The translation: a company pivoting from a regional generics factory toward a global innovation play, one partnership at a time.

3. Business Model: WTF Do They Even Do?

The generics business—the old spine.

Glenmark fills scripts in the USA (oral solids, injectables, respiratory devices), maintains a portfolio of ₹206 authorized generics (as of FY26), and filed ₹6 ANDAs in FY26, with targets of 5 more filings annually. The company ranks 13th in US generic prescriptions by volume, but the margin compression in this segment is real: a ₹520 crore market in the USA for fluticasone MDI alone, and the first-to-file advantage lasts 180 days. Glenmark captured that in Q4 FY26, then faced supply-chain delays that neutered the quarter’s upside. The Monroe, North Carolina facility—critical for injectable commercialization—spent much of FY25 and FY26 mothballed pending FDA inspection, resuming manufacturing only in Q4.

The branded India & emerging markets business—the new heavyweight.

In India, Glenmark ranked #2 in respiratory, #2 in dermatology, and #5 in cardiac (FY26). Eleven brands generate ₹500+ crore in annual sales; two clear ₹1,000 crore. Secondary sales (invoiced to the channel, not to the patient) grew 13.5% in FY26, beating the IPM benchmark of 9%. In Russia, the company grew secondary sales 11% (MAT March 2026), lifted respiratory/dermatology franchises, and ranked #8 in dermatology by March 2026. LATAM, MENA, and APAC added multiple respiratory launches and double-digit secondary growth in key pockets (Malaysia, Australia, Kenya, South Africa).

Ryaltris (allergic rhinitis nasal spray), the global flagship branded specialty product, hit 55 markets by Q4 FY26, with cumulative sales of ~USD 100 crore since FY23. Management guided 30–40% annual growth for the next few years and flagged 8–10 additional market launches in FY27, including Brazil (described as a “big commercial launch”) and China (launched Q4 post-reimbursement). Glenmark shifted to direct US commercialization of Ryaltris from April 1, 2026, replacing a third-party distributor.

Specialty dermatology (WINLEVI, JABRYUS, partnered assets) is nascent but ramping. WINLEVI launched across key European markets on June 11, 2026. The company’s first systemic oral dermatology treatment, Jabris (abrocitinib), achieved strong prescriber uptake in India post-launch.

The innovation moat—still under construction.

Ichnos Sciences Inc., Glenmark’s USA-based subsidiary, owns a proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) platform for multispecific antibodies. ISB 2001 (a trispecific targeting CD38, BCMA, and CD3) is in Phase 1 for multiple myeloma, with >145 subjects dosed as of the concall. The AbbVie licensing deal ($700m upfront + $1.225bn in potential milestones + tiered double-digit royalties) validates the platform but ties the company’s innovation narrative to AbbVie’s regulatory and commercial execution outside most of the USA and the EU. ISB 2301 (a pentaspecific for solid tumors) targets an IND filing by end-CY26.

Glenmark also licensed multiple branded oncology assets: Trastuzumab Rezetecan (HER2 ADC, from Hengrui), Aumolertinib (3rd-gen EGFR TKI, from Hanso), and Envafolimab (partner Alpha Mab). First MA filings are expected H2 FY27 for Trastozuma Brazetican; H2 FY27 launches are planned for Omylertinib in India/EM; FY28 launches for Envafolimab.

The risk is obvious: Glenmark is commercializing other companies’ drugs and betting that the BEAT platform, with ~1.3k patents granted (1,343 cumulative as of FY26), will eventually return capital via partnerships and out-licensing milestones. The AbbVie deal suggests investor appetite exists; the company’s plan to target 1 IND filing per year assumes R&D productivity will hold.

4. Financials Overview

Figures are consolidated, in ₹ crore.

The operating profit line requires context. FY26 included ₹323 crore in litigation settlement expenses (antitrust suits in the US, resolved in May 2026 for USD 29.6m plus $6.1m over the next 5 years). Adjusted for this and other one-time expenses (~₹373 crore in total exceptional items), the core operating profit stood at ~₹4,450 crore, implying a normalized operating margin of ~26%.

Revenue composition by region (FY26):

Consolidated revenue of ₹16,983 crore broke down approximately as:

• India formulations: ~₹4,050 crore (implied from ₹10,201 crore Q4 run-rate and segment disclosures)
• North America: ~₹4,100 crore (approximately 24% of consolidated revenue)
• Europe: ~₹3,050 crore (approximately 18% of consolidated revenue)
• Emerging Markets (ex-API): ~₹3,570 crore (approximately 21% of consolidated revenue)
• API: ~₹2,030 crore (approximately 12% of consolidated revenue)

Key drivers (from concall & presentations):

Management attributed the 27.5% revenue growth to broad-based strength: US generic launches (13 ANDAs approved in FY26, 4 in Q4 alone), India secondary sales growth of 13.5% (vs. 9% IPM), Europe branded business acceleration (UK, Spain, Germany), and Ryaltris international rollout (50%+ secondary growth across commercial markets in FY26, ex-AbbVie